The National Academies: Advisers to the Nation on Science, Engineering, and Medicine
NATIONAL ACADEMY OF SCIENCES NATIONAL ACADEMY OF ENGINEERING INSTITUTE OF MEDICINE NATIONAL RESEARCH COUNCIL
Current Operating Status

The National Academies Testimony before Congress

Public Laws Containing Studies for the National Academies

Briefings to Congress

Congressionally Mandated Reports

Policy Statements and Historical Documents

The OCGA staff

Request a Report (Congressional and Government Staff Only)


Mailing Address:
The Office of Congressional and Government Affairs
The Keck Center of the National Academies
Keck WS1008
500 Fifth Street, NW
Washington, DC 20001
Tel: (202) 334-1601
Fax: (202) 334-2419

Back to Main Page


Title of Law:Department of Defense Appropriations Act, 2000
Law #:Public Law 106- 79
Passed by Congress:106th Congress (1st Session)

The following are excerpts, highlighted in red, from the final legislation and/or conference report which contain National Academies’ studies. (Pound signs [##] between passages denote the deletion of unrelated text.)

HRpt 106-371 CONFERENCE REPORT to accompany H.R. 2561 MAKING APPROPRIATIONS FOR THE DEPARTMENT OF DEFENSE FOR THE FISCAL YEAR ENDING SEPTEMBER 30, 2000, AND FOR OTHER PURPOSES
Conference Committee
(10/08/99)
--- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---

######

ANTHRAX VACCINE IMMUNIZATION PROGRAM (AVIP)

The Comptroller General shall study the immunization program and report on the following: effects on military morale, retention, and recruiting; the civilian costs and burdens associated with adverse reactions for members of the reserve components; adequacy of long- and short-term health monitoring; assessment of the anthrax threat, including

but not limited to foreign doctrine, weaponization, quality of intelligence, and other biological threats. A classified annex may be submitted to meet this requirement.

The Department is directed to enter into a contract with the National Research Council to independently study the effectiveness and safety of the anthrax vaccine. The following issues shall be considered in the report: the types and severity of adverse reactions, including gender differences; long-term health implications; inhalational efficacy of the

vaccine against all known anthrax strains; correlation of animal models to safety and effectiveness in humans; validation of the manufacturing process focusing on, but not limited to discrepancies identified by the Food and Drug Administration in February 1998; definition of vaccine components in terms of the protective antigen and other bacterial products and constituents; identification of gaps in existing research.

Preliminary reports addressing these issues will be submitted to the Committee on Appropriations and the Committee on Armed Services of both the House and the Senate by April 1, 2000.

######

RSS News Feed | Subscribe to e-newsletters | Feedback | Back to Top